This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data In Relapsed Hodgkin Lymphoma And Other CD30-Positive Malignancies From Multiple Presentations At ASH Annual Meeting

Data highlights were:

  • Of the 14 patients evaluable at the time of this analysis, the objective response rate was 85.7 percent (12 of 14 patients), including 50 percent (seven of 14 patients) with a complete remission and 35.7 percent (five of 14 patients) with a partial remission. Two patients achieved stable disease after four cycles of therapy. No patients developed progressive disease while on treatment.
  • At the time of data analysis, a total of seven of 14 patients had undergone stem cell mobilization after the fourth dose of ADCETRIS and 100 percent of these patients achieved complete remission after stem cell transplantation. The other seven patients were still undergoing stem cell mobilization or had not completed ADCETRIS treatment.
  • The most common adverse events of Grade 1 or 2 were peripheral sensory neuropathy (42.9 percent), rash acneiform (35.7 percent), AST elevation (28.6 percent) and fatigue (28.6 percent).
  • Grade 3 adverse events were rash acneiform (7.1 percent) and urinary tract infection (7.1 percent). There were no Grade 4 adverse events.

ADCETRIS is not approved for salvage HL patients who are deemed eligible for ASCT. There are multiple ongoing investigator-sponsored trials being conducted evaluating ADCETRIS as a salvage HL therapy, and a phase I/II clinical trial evaluating ADCETRIS with bendamustine in this setting will be initiated by the end of 2012.

Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies (Abstract #3687)

A retrospective analysis was conducted in patients at least 60 years or older with CD30-positive hematologic malignancies who had received at least one dose of ADCETRIS in one or more of seven clinical trials. The analysis assessed the efficacy and safety of single-agent ADCETRIS among 22 systemic anaplastic large cell lymphoma (sALCL) patients, 16 HL patients and two patients with other CD30-positive malignancies.

Stock quotes in this article: SGEN 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs